Suppr超能文献

澳大利亚在血栓栓塞性疾病风险增加患者中使用下腔静脉滤器回收的初步经验。

Initial Australian experience with the recovery inferior vena cava filter in patients with increased risk of thromboembolic disease.

作者信息

de Villiers L, Mackenzie S, Gibbs H, Leggett D, Neels M, Harper J

机构信息

Department of Radiology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

出版信息

J Med Imaging Radiat Oncol. 2008 Apr;52(2):124-9. doi: 10.1111/j.1440-1673.2008.01929.x.

Abstract

Inferior vena cava (IVC) filters are an alternative treatment in venous thromboembolism where there are contraindications to anticoagulation. There are, however, concerns about the long-term safety of permanent IVC filters. Often, the period of risk from anticoagulation therapy is short, which supports the use of non-permanent IVC filters. In this series, 54 Recovery Filters (Bard, Tempe, AZ, USA) were placed since its approval for use in Australia in March 2004 (approved for removal up to 160 days after insertion). The most common indication for filter placement in this series was established thromboembolic disease with a temporary contraindication to anticoagulation. Twenty-two filters were successfully retrieved without complication. In one case, it was not possible to retrieve the filter because of extensive contained thrombus. No complication was experienced at filter placement or retrieval; however, a fatal complication occurred as a result of filter migration. Mean time from placement to retrieval was 48 days (range 7-90 days). We describe methods we found useful at filter retrieval to overcome filter tilting.

摘要

下腔静脉(IVC)滤器是静脉血栓栓塞症抗凝治疗有禁忌时的一种替代治疗方法。然而,对于永久性IVC滤器的长期安全性存在担忧。通常,抗凝治疗的风险期较短,这支持使用非永久性IVC滤器。在本系列研究中,自2004年3月其在澳大利亚获批使用(获批在插入后160天内取出)以来,共植入了54个Recovery滤器(美国巴德公司,亚利桑那州坦佩)。本系列中植入滤器最常见的适应证是已确诊的血栓栓塞性疾病且存在抗凝治疗的临时禁忌。22个滤器成功取出,无并发症发生。有1例因大量包裹性血栓而无法取出滤器。滤器植入或取出时均未发生并发症;然而,发生了1例因滤器移位导致的致命并发症。从植入到取出的平均时间为48天(范围7 - 90天)。我们描述了在滤器取出时发现的有助于克服滤器倾斜的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验